<DOC>
	<DOCNO>NCT01472991</DOCNO>
	<brief_summary>Study assess TC-5619 improves symptom adult diagnose inattentive-predominant subtype ADHD 4-week treatment period .</brief_summary>
	<brief_title>Safety &amp; Efficacy TC-5619 Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>A 3-arm , double-blind , randomize , placebo-controlled , multicenter , fix dose study assess efficacy safety TC-5619 adult inattentive-predominant attention deficit/hyperactivity disorder ( ADHD ) utilize Connor 's Adult ADHD Rating Scale-Investigator Completed Version ( CAARS-INV ) inattentive subscale score 4 week treatment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1 . Diagnosis Inattentive predominant ADHD per DSMIV TR ) criteria Screening 2 . Score ≥ 2 least 6 9 item inattentive subscale CAARSINV Baseline ( Day 1 ) 3 . Score &lt; 2 least 4 9 item hyperactive/impulsivity subscale CAARSINV Baseline ( Day 1 ) 4 . Score ≥ 4 ( least moderate ) CGIS 5 . Tobacco nonusers indicate lack tobacco use within last 6 month prior Screening , negative urinary cotinine level &lt; 50 ng/mL quantification 1 . Current DSMIV Axis I psychiatric disorder ADHD ; 2 . Use tobacco cessation agent within 4 week prior Screening 3 . Known suspected drug abuse within last 6 month prior Screening 4 . Urine drug screen positive illegal nonprescribed drug Screening 5 . Patients imminent risk suicide danger others judge investigator 6 . Use drug affect cognitive function within 4 week prior Day 1 . This include use concomitant medication treatment ADHD . 7 . History significant major unstable neurological , metabolic , hepatic , renal , hematological , pulmonary , cardiovascular ( CV ) , gastrointestinal ( GI ) , urological disorder ; diagnosis major depressive disorder 8 . Myocardial infarction within past year 9 . Seizure disorder within past year 10 . Type 1 diabetes mellitus ( DM ) ; type 2 DM require medication ( dietcontrolled allow ) 11 . HbA1C &gt; 7.4 Screening 12 . BMI &lt; 15 &gt; 35 ; male weight &lt; 100 lb ; female weight &lt; 80 lb . 13 . Current tuberculosis ( TB ) know systemic infection [ Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) , Human Immunodeficiency Virus ( HIV ) ] 14 . Women childbearing potential male participant unwilling unable use accept method birth control 15 . Participation another Central Nervous System ( CNS ) relate clinical trial last 3 month clinical trial last 30 day prior Screening , participation previous TC5619 clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>ADHD</keyword>
</DOC>